BeiGene Priced, Nasdaq: BGNE

Chinese biotech developing cancer therapies for China and global markets.

Industry: Health Care

Latest Trade: $45.55 0.00 (0.0%)

First Day Return: +18.0%

Return from IPO: +89.8%

Industry: Health Care

We are a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapies and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. We further believe that discovery of next-generation cancer therapies requires new research tools. To that end, we have developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort.
more less
IPO News for BeiGene
more
IPO Data
IPO File Date 10/16/2015
Offer Price $24.00
Price Range $22.00 - $24.00
Offer Shares (mm) 6.6
Deal Size ($mm) $158
IPO Data
IPO Date 02/02/2016
Offer Price $24.00
Price Range $22.00 - $24.00
Offer Shares (mm) 6.6
Deal Size ($mm) $158
Underwriters
more
Company Data
Headquarters Beijing, China
Founded 2010
Employees 192
Website www.beigene.com